Maravai LifeSciences Holdings Inc. Class A Common Stock vs US Foods Holding Corp. Common Stock — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M), while US Foods Holding Corp. Common Stock trades at $98.45 (market cap $21.18B). The key difference: US Foods Holding Corp. Common Stock is far larger — about 21.8× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Maravai LifeSciences Holdings Inc. Class A Common Stock is more actively traded (4,325,710 versus 1,065,315). Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and US Foods Holding Corp. Common Stock for 6 Days on average.
| MRVI | USFD | |
|---|---|---|
Market Cap | $972.90M | $21.18B |
Volume | 4,325,710 | 1,065,315 |
Sector | Health | Consumer Staples |
52-Week High | $9.00 | $110.94 |
52-Week Low | $2.83 | $70.05 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $1.08B | $26.53B |
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
US Foods (USFD) trades at $97.91, showing modest daily gains of 0.21%. The stock maintains a bullish technical trend with strong moving average support and trades near key resistance at $98. Fundamentally, the company demonstrates solid revenue growth with $39.42B in 2025 sales and improving profitability, though net margins remain thin at 1.81%. Recent business developments include new product launches and conference participation, signaling ongoing operational momentum.
The outlook remains positive with analyst consensus strongly favoring Buy ratings (73%) and a $117 price target suggesting 19% upside. Key opportunities include margin expansion and market share gains, while risks involve competitive pressures and execution challenges in a low-margin industry. The combination of technical strength, fundamental improvement, and Wall Street support positions USFD favorably for continued growth.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →US Foods distributes food and related products to foodservice operators. Its customers include restaurants, healthcare providers, hospitality businesses, government institutions, and educational organizations.
Read more on USFD →